Nearly 40 years after HIV was first identified, the virus continues its devastating march across the globe. Today, 38 million people live with HIV, and each year brings 1.5 million new infections and ...

For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...

Gilead stock slumped late Thursday on soft product sales and lighter-than-expected revenue from its newcomer HIV prevention ...

People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...

Return to shareholders -- $1.4 billion was returned to shareholders as of fiscal Q3 2025 through dividends and share repurchases. Anticipated step-up in expenses -- Research and development, as well ...

Dzidzai is one of 25 Community Adolescent Treatment Supporters (CATS) trained by the National Aids Council (NAC) and the ...

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

More than 230 people became infected with HIV in Indiana, worsened by delayed action from former Gov. Mike Pence. Experts and ...

More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...

Researchers used cryo-EM to study how the HIV enzyme integrase arranges in 3D to slip its DNA into the host genome and pack ...